End-of-day quote
Bucharest S.E.
03:30:00 29/04/2024 am IST
|
5-day change
|
1st Jan Change
|
0.822
RON
|
-0.48%
|
|
-0.96%
|
-0.24%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
320.2
|
357.7
|
421.7
|
821.8
|
607
|
811.9
|
Enterprise Value (EV)
1 |
274.6
|
266.6
|
346.2
|
717.9
|
524.3
|
700.3
|
P/E ratio
|
8.9
x
|
7.53
x
|
8.34
x
|
14.7
x
|
9.31
x
|
11.6
x
|
Yield
|
6.15%
|
5.79%
|
5.14%
|
2.88%
|
4.87%
|
3.76%
|
Capitalization / Revenue
|
1.74
x
|
1.83
x
|
1.95
x
|
3.44
x
|
2.19
x
|
2.9
x
|
EV / Revenue
|
1.49
x
|
1.36
x
|
1.6
x
|
3
x
|
1.89
x
|
2.5
x
|
EV / EBITDA
|
4.69
x
|
3.86
x
|
4.64
x
|
8.69
x
|
5.55
x
|
7.63
x
|
EV / FCF
|
8.76
x
|
5.06
x
|
-34.6
x
|
17.7
x
|
-26.3
x
|
20.3
x
|
FCF Yield
|
11.4%
|
19.8%
|
-2.89%
|
5.64%
|
-3.81%
|
4.93%
|
Price to Book
|
1.42
x
|
1.39
x
|
1.45
x
|
2.47
x
|
1.6
x
|
1.87
x
|
Nbr of stocks (in thousands)
|
9,85,367
|
9,85,367
|
9,85,367
|
9,85,367
|
9,85,367
|
9,85,367
|
Reference price
2 |
0.3250
|
0.3630
|
0.4280
|
0.8340
|
0.6160
|
0.8240
|
Announcement Date
|
19/06/19
|
28/04/20
|
26/04/21
|
28/04/22
|
26/04/23
|
24/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
184.2
|
195.3
|
216.4
|
239
|
277
|
280.3
|
EBITDA
1 |
58.56
|
69.14
|
74.62
|
82.59
|
94.45
|
91.77
|
EBIT
1 |
46.5
|
60.91
|
63.67
|
68.87
|
78.95
|
74.81
|
Operating Margin
|
25.24%
|
31.18%
|
29.42%
|
28.81%
|
28.51%
|
26.69%
|
Earnings before Tax (EBT)
1 |
47.17
|
62.47
|
64.85
|
69.55
|
80.88
|
83.71
|
Net income
1 |
38.42
|
50.88
|
54.26
|
60.36
|
70.92
|
77.01
|
Net margin
|
20.86%
|
26.05%
|
25.07%
|
25.25%
|
25.6%
|
27.48%
|
EPS
2 |
0.0365
|
0.0482
|
0.0513
|
0.0569
|
0.0662
|
0.0713
|
Free Cash Flow
1 |
31.34
|
52.69
|
-9.998
|
40.47
|
-19.96
|
34.51
|
FCF margin
|
17.01%
|
26.97%
|
-4.62%
|
16.93%
|
-7.21%
|
12.31%
|
FCF Conversion (EBITDA)
|
53.51%
|
76.2%
|
-
|
49%
|
-
|
37.6%
|
FCF Conversion (Net income)
|
81.55%
|
103.55%
|
-
|
67.06%
|
-
|
44.81%
|
Dividend per Share
2 |
0.0200
|
0.0210
|
0.0220
|
0.0240
|
0.0300
|
0.0310
|
Announcement Date
|
19/06/19
|
28/04/20
|
26/04/21
|
28/04/22
|
26/04/23
|
24/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
45.6
|
91.1
|
75.5
|
104
|
82.7
|
112
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
31.3
|
52.7
|
-10
|
40.5
|
-20
|
34.5
|
ROE (net income / shareholders' equity)
|
17.4%
|
21.1%
|
19.8%
|
19.3%
|
19.9%
|
18.9%
|
ROA (Net income/ Total Assets)
|
10.6%
|
12%
|
11.1%
|
10.9%
|
11.1%
|
9.74%
|
Assets
1 |
362.2
|
422.4
|
490.2
|
554.7
|
636.2
|
790.9
|
Book Value Per Share
2 |
0.2300
|
0.2600
|
0.3000
|
0.3400
|
0.3900
|
0.4400
|
Cash Flow per Share
2 |
0.0500
|
0.0900
|
0.0600
|
0.1100
|
0.0800
|
0.0200
|
Capex
1 |
20.9
|
19.8
|
27.5
|
21.5
|
30.1
|
29.8
|
Capex / Sales
|
11.32%
|
10.13%
|
12.7%
|
8.97%
|
10.88%
|
10.65%
|
Announcement Date
|
19/06/19
|
28/04/20
|
26/04/21
|
28/04/22
|
26/04/23
|
24/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -0.24% | 174M | | +20.53% | 43.75B | | +22.95% | 22.06B | | +13.30% | 14.46B | | +13.34% | 13.62B | | +39.30% | 11.61B | | -9.60% | 6.9B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +9.64% | 5.32B |
Generic Pharmaceuticals
|